Pharmacyclics in brief
Pharmacyclics is an unlisted company in the Biotechnology industry, based in Sunnyvale, USA. It was founded in 1991. In the year to December 2014 it had sales of $730 M and a net profit of $86 M, about 12 cents of profit for every dollar of sales.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Pharmacyclics
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Pharmacyclics timeline
- 1991
- 🏁· approximateFounded
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Pharmacyclics from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Pharmacyclics
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 26 May 2015 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 11.8%
- Operating margin
- 16.8%
- Return on equity
- 10.4%
- Liabilities / assets
- 21.8%
- Revenue growth
- +180.5%
- R&D / revenue
- 23.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2014 | $730M | +180.5% | $122M | $86M | 11.8% |
| Dec 2013 | $260M | +217.3% | $98M | $67M | 25.8% |
| Jun 2012 | $82M | +896.2% | $12M | $12M | 14.6% |
| Jun 2011 | $8M | -11.6% | $-35M | $-35M | -427.7% |
| Jun 2010 | $9M | — | $-16M | $-15M | -161.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2014 | $184M | $14M | $170M | $1.10 | — |
| Dec 2013 | $89M | $18M | $70M | $0.87 | — |
| Jun 2012 | $86M | $3M | $83M | $0.17 | — |
| Jun 2011 | $-22M | $1M | $-23M | $-0.59 | — |
| Jun 2010 | $-15M | $0M | $-16M | $-0.31 | — |
SEC filings
- May 26, 20158-KCurrent reportAcquisition or disposal completed · Listing notice · Change in control · Bylaws amended · Other events
- May 4, 201510-QQuarterly report · period to Mar 2015
- May 1, 20158-KCurrent reportResults of operations
- Apr 8, 201510-K/AAnnual report (amended) · period to Dec 2014
- Mar 23, 20158-KCurrent reportMaterial agreement
- Mar 17, 20158-KCurrent reportOther events
- Mar 6, 20158-KCurrent reportMaterial agreement · Directors or officers changed · Bylaws amended · Other events
- Mar 5, 20158-KCurrent reportOther events
- Feb 20, 20158-KCurrent reportRegulation FD disclosure
- Feb 18, 201510-KAnnual report · period to Dec 2014
- Feb 18, 20158-KCurrent reportResults of operations
- Feb 2, 20158-KCurrent reportOther events
Official filings of Pharmacyclics with the US Securities and Exchange Commission.
Annual results
- Revenue
- $730 M
- Operating income
- $122 M
- Net income
- $86 M
For year ending December-2014 · source: SEC filing
Balance sheet
- Total assets
- $1.1 B
- Total liabilities
- $231 M
- Total equity
- $829 M
As of December-2014
Insider trading at Pharmacyclics#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David Duane SmithDirector | Tender in a change of control | -3,000 | $261.25 | $784 K | 0 | Form 4 |
| filed | Robert F. BoothDirector | Disposal to the company | -10,000 | $261.25 | $2.6 M | 0 | Form 4 |
| filed | Richard Van Den BroekDirector | Tender in a change of controlindirect | -29,610 | $261.25 | $7.7 M | 0 | Form 4 |
| filed | Eric H. HalvorsonDirector | Tender in a change of control | -1,000 | $261.25 | $261 K | 0 | Form 4 |
| filed | Heow TanChief Quality&Tech Operations | Tender in a change of control | -11,721 | $261.25 | $3.1 M | 0 | Form 4 |
| filed | Maky ZanganehChief Operating Officer | Disposal to the company | -15,000 | $261.25 | $3.9 M | 351,293 | Form 4 |
| filed | Shawn TomaselloChief Commercial Officer | Disposal to the company | -50,000 | $261.25 | $13.1 M | 7,302 | Form 4 |
| filed | Manmeet Singh SoniChief Financial Officer | Disposal to the company | -54,000 | $261.25 | $14.1 M | 873 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Pharmacyclics scorecard#
Passes 10 of the 12 checks that could be worked out: strongest in growth (4 of 4), weakest in profitability (3 of 5). Fiscal year 2014.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth4 of 4
- ✓Revenue grew in the newest year180.5%Revenue up 180.5% in fiscal 2014.
- ✓Revenue up more than 5% a year over three years345.9%345.9% a year over the three years to fiscal 2014.
- ✓Faster growth over three years than its peers' median345.9%345.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year1.10 vs 0.87Diluted EPS 1.10 in fiscal 2014 against 0.87 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability3 of 5
- ✓Profitable in the newest year$86 MNet income $86 M in fiscal 2014.
- ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2014.
- ✓Operating margin above its peers' median16.8%16.8% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%11.8%11.8% in fiscal 2014.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier16.8%16.8% in fiscal 2014 against -429.8% in 2011.
Financial health2 of 2
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.23 at the end of fiscal 2014.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2014.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2014.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Pharmacyclics: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Jun 30, 2012 | FY 2011to Jun 30, 2011 | FY 2010to Jun 30, 2010 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 730+180%100% | 260+217%100% | 82+896%100% | 8.2−11.5%100% | 9.3—100% | |
| Cost of revenue | 40+1054%5.5% | 3.5—1.3% | 0—0.0% | 0—0.0% | — | |
| Research and development | 172+103%23.6% | 85+56.1%32.7% | 55+58.2%66.5% | 34+98.7%419% | 17—187% | |
| Selling, general and administrative | 168+128%23.0% | 74r104+373%28.3% | 16+70.7%19.0% | 9.1—111% | — | |
| General and administrative | — | — | 16+70.7%19.0% | 9.1+20.7%111% | 7.6—81.2% | |
| Operating expenses | — | — | 70+60.8%85.5% | 44+75.0%530% | 25—268% | |
| Total costs and expenses | 607+274%83.2% | 162+131%62.4% | 70+60.8%85.5% | 44—530% | — | |
| Operating income | 122+25.0%16.8% | 98+724%37.6% | 12—14.5% | −35—−430% | −16—−168% | |
| Interest and finance income | — | — | 0.2+5.3%0.2% | 0.2+109%2.1% | 0.1—0.9% | |
| Other non-operating income (expense) | −0.4—−0.1% | −0.1—−0.0% | −0.0−1650%−0.0% | 0.0—0.0% | −0.0—−0.5% | |
| Income before tax | 122+24.8%16.8% | 98+716%37.7% | 12—14.7% | −35—−428% | −16—−167% | |
| Income tax | 36+16.7%5.0% | 31+79710%12.0% | 0.0—0.0% | 0—0.0% | −0.6—−5.9% | |
| Net income attributable to shareholders | 86+28.5%11.8% | 67+459%25.8% | 12—14.6% | −35—−428% | −15—−161% | |
| Earnings per share, basic | 1.14+23.9%— | 0.92+441%— | 0.17—— | -0.59—— | -0.31—— | |
| Earnings per share, diluted | 1.10+26.4%— | 0.87+412%— | 0.17—— | -0.59—— | -0.31—— | |
| Shares, weighted average (basic) | 75+3.4%— | 73+5.9%— | 69+14.6%— | 60+24.1%— | 48—— | |
| Shares, weighted average (diluted) | 78+1.4%— | 77+6.2%— | 73+21.1%— | 60+24.1%— | 48—— | |
| Balance sheet | ||||||
| Cash and cash equivalents | 845+35.4%79.7% | 624+215%81.2% | 198+126%90.3% | 88+71.4%75.4% | 51—— | |
| Receivables | 64+482%6.1% | 11+86.4%1.4% | 5.9r6.0+12504%2.7% | 0.0r0.1—0.0% | — | |
| Inventory | 34+173%3.2% | 13—1.6% | — | — | — | |
| Other current assets | 21+122%1.9% | 9.3+139%1.2% | 3.9r3.8+66.6%1.8% | 2.3r2.3—2.0% | — | |
| Current assets | 1,016+37.1%95.8% | 741+247%96.4% | 213+86.1%97.4% | 115—98.6% | — | |
| Property, plant and equipment | 32+27.5%3.1% | 25+563%3.3% | 3.8+193%1.8% | 1.3—1.1% | — | |
| Other intangible assets | 8.7—0.8% | 0—0.0% | — | — | — | |
| Total assets | 1,060+37.9%100% | 769+251%100% | 219+88.3%100% | 116—100% | — | |
| Accounts payable | 7.3+81.7%0.7% | 4.0+52.3%0.5% | 2.6r9.2+210%1.2% | 0.9r5.7—0.7% | — | |
| Current liabilities | 194+122%18.3% | 88+362%11.4% | 19+33.1%8.7% | 14—12.3% | — | |
| Total liabilities | 231+63.6%21.8% | 141+62.2%18.4% | 87+493%39.7% | 15—12.6% | — | |
| Retained earnings | −130—−12.3% | −217—−28.2% | −401—−183% | −413—−355% | — | |
| Shareholders' equity | 829+32.1%78.2% | 628+375%81.6% | 132+29.9%60.3% | 102+52.3%87.4% | 67—— | |
| Total liabilities and equity | 1,060+37.9%100% | 769+251%100% | 219+88.3%100% | 116—100% | — | |
| Shares outstanding | 76+2.4%— | 74+7.0%— | 69+2.1%— | 68r68—— | — | |
| Cash-flow statement | ||||||
| Depreciation and amortization | 3.9+77.3%0.5% | 2.2r2.2+267%0.8% | 0.6r0.6+105%0.7% | 0.3+24.3%3.5% | 0.2—2.5% | |
| Share-based compensation | 54+7.0%7.4% | 50+409%19.3% | 9.9+26.3%12.0% | 7.8+145%95.0% | 3.2—34.3% | |
| Cash from operating activities | 184+107%25.2% | 89+3.1%34.1% | 86—105% | −22—−271% | −15—−166% | |
| Capital expenditure | −14—−1.9% | −18—−7.0% | −3.0—−3.6% | −1.2—−14.0% | −0.2—−2.4% | |
| Intangible assets bought | −9.3—−1.3% | 0—0.0% | 0—0.0% | — | — | |
| Cash from investing activities | −23—−3.2% | −20−228%−7.8% | 16—19.3% | −3.7—−44.4% | −22—−234% | |
| Shares issued | 0−100%0.0% | 201—77.3% | −0.6−101%−0.7% | 57−21.9%687% | 73—779% | |
| Cash from financing activities | 61−75.5%8.3% | 248+2909%95.3% | 8.2−86.8%10.1% | 62−15.5%759% | 74—794% | |
| Change in cash | 221−30.2%30.3% | 317+187%122% | 110+201%134% | 37−0.3%444% | 37—394% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Mar 31, 2015 | Q1 FY2015to Mar 31, 2015 | Q4 FY2014to Dec 31, 2014 | Q3 FY2014to Sep 30, 2014 | Q2 FY2014to Jun 30, 2014 | Q1 FY2014to Mar 31, 2014 | Q4 FY2013to Dec 31, 2013 | Q3 FY2013to Sep 30, 2013 | Q2 FY2013to Jun 30, 2013 | Q1 FY2013to Mar 31, 2013 | Q4 FY2012to Jun 30, 2012 | Q3 FY2012to Mar 31, 2012 | Q2 FY2012to Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 816+117%100% | 206+72.4%100% | 290+135%100% | 207+162%100% | 113+107%100% | 119+4095%100% | 124+5720%100% | 79+4004%100% | 55−29.8%100% | 2.8—100% | 2.1—100% | 1.9—100% | 78—100% | |
| Cost of revenue | 51+431%6.2% | 17+173%8.1% | 13*+282%4.6% | 12—5.6% | 9.3—8.2% | 6.1—5.1% | 3.5*—2.8% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | |
| Research and development | 187+120%22.9% | 49+39.9%24.0% | 48*+352%16.4% | 44+303%21.2% | 46+63.5%40.4% | 35−1.4%29.6% | 11*−31.7%8.5% | 11−31.0%13.8% | 28+131%51.1% | 36—1257% | 15—725% | 16—821% | 12—15.5% | |
| Selling, general and administrative | 183+107%22.4% | 50+42.6%24.1% | 50*+108%17.3% | 38+158%18.3% | 45+206%39.8% | 35+73.3%29.1% | 24r55*—19.5% | 15—18.6% | 15—26.9% | 20—704% | — | — | — | |
| General and administrative | — | — | — | — | — | — | — | 15+263%18.6% | 15+273%26.9% | — | 4.2—199% | 4.1—211% | 3.9—5.1% | |
| Operating expenses | — | — | — | — | — | — | — | 26+29.0%32.4% | 43+166%78.0% | 56—1961% | 20—923% | 20—1032% | 16—20.6% | |
| Total costs and expenses | 708+241%86.8% | 202+99.7%98.2% | 197+417%68.0% | 159+519%76.6% | 150+252%133% | 101+81.2%84.7% | 38+94.4%30.9% | 26+29.0%32.4% | 43—78.0% | 56—1961% | 20—923% | 20—1032% | — | |
| Operating income | 108−36.2%13.2% | 3.8−79.3%1.8% | 93+8.8%32.0% | 48−9.5%23.4% | −37−409%−32.9% | 18—15.3% | 85—69.1% | 53—67.6% | 12−80.6%22.0% | −53—−1861% | −17—−823% | −18—−932% | 62—79.4% | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0.1+233%0.2% | 0.1—2.7% | 0.0—2.3% | 0.1—3.2% | 0.0—0.0% | |
| Other non-operating income (expense) | — | 0.3—0.1% | — | — | −0.1—−0.1% | −0.0−1500%−0.0% | — | — | −0.1—−0.2% | 0.0—0.1% | −0.0—−0.1% | −0.0—−0.3% | −0.0—−0.0% | |
| Income before tax | 108−36.0%13.3% | 4.2−76.8%2.1% | 93*+8.9%32.1% | 48−9.7%23.4% | −37−410%−32.9% | 18—15.3% | 85*—69.2% | 54—67.7% | 12−80.6%22.0% | −53—−1858% | −17—−821% | −18—−929% | 62—79.5% | |
| Income tax | 36+13.5%4.5% | 0.1—0.0% | 30*+39.5%10.2% | 6.9−38.2%3.4% | −0.2—−0.2% | −0.0—−0.0% | 21*—17.2% | 11—14.2% | −0.3−106%−0.6% | −1.0—−34.2% | −0.5—−24.9% | −5.1—−264% | 5.7—7.3% | |
| Net income attributable to shareholders | 72−47.5%8.8% | 4.1−77.3%2.0% | 63−1.2%21.9% | 41−2.2%20.0% | −37−400%−32.8% | 18—15.3% | 64—52.0% | 42—53.5% | 12−78.0%22.6% | −52—−1824% | −17—−796% | −13—−665% | 56—72.2% | |
| Earnings per share, basic | 0.95−48.9%— | 0.05−79.2%— | 0.84−3.4%— | 0.55−5.2%— | -0.49−388%— | 0.24—— | 0.87—— | 0.58—— | 0.17−79.3%— | -0.73—— | -0.24—— | -0.19—— | 0.82—— | |
| Earnings per share, diluted | 0.90−48.9%— | 0.05−78.3%— | 0.81−1.2%— | 0.53−3.6%— | -0.49−406%— | 0.23—— | 0.82—— | 0.55—— | 0.16−79.5%— | -0.73—— | -0.24—— | -0.19—— | 0.78—— | |
| Shares, weighted average (basic) | 76+1.9%— | 76+1.9%— | 76+2.5%— | 75+2.8%— | 75+3.0%— | 75+5.4%— | 74+6.9%— | 73+6.5%— | 73+6.3%— | 71—— | 69—— | 69r0.1—— | 69r0.1—— | |
| Shares, weighted average (diluted) | 79+1.5%— | 79+1.5%— | 78+0.7%— | 78r78+0.5%— | 75−2.7%— | 78+10.1%— | 78+12.8%— | 78+12.8%— | 77+7.6%— | 71—— | 69—— | 69r0.1—— | 72r0.1—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 875—78.0% | 875+28.9%78.0% | 845+35.4%79.7% | 725+32.1%79.9% | 666+34.8%80.7% | 679+35.0%84.2% | 624+215%81.2% | 548+157%84.6% | 494+115%86.6% | 503—92.2% | 198—90.3% | 213—91.2% | 230—92.9% | |
| Receivables | 77—6.9% | 77+185%6.9% | 64+482%6.1% | 53−0.8%5.9% | 45+21.2%5.5% | 27+57.4%3.4% | 11+86.4%1.4% | 54+317%8.3% | 37+3095%6.6% | 17—3.1% | 5.9r6.0—2.7% | 13—5.5% | 1.2—0.5% | |
| Inventory | 49—4.4% | 49+70.7%4.4% | 34+173%3.2% | 41—4.6% | 38—4.6% | 29—3.6% | 13—1.6% | — | — | — | — | — | — | |
| Other current assets | 40—3.6% | 40+252%3.6% | 21+122%1.9% | 15+44.3%1.7% | 12+13.8%1.5% | 11+167%1.4% | 9.3+139%1.2% | 11+301%1.6% | 11+218%1.9% | 4.3—0.8% | 3.9r3.8—1.8% | 2.6—1.1% | 3.4—1.4% | |
| Current assets | 1,078—96.1% | 1,078+39.4%96.1% | 1,016+37.1%95.8% | 863+38.2%95.2% | 784+41.6%94.8% | 773+45.1%95.9% | 741+247%96.4% | 624+171%96.3% | 553+126%96.9% | 533—97.7% | 213—97.4% | 230—98.5% | 245—98.8% | |
| Property, plant and equipment | 32—2.9% | 32+7.9%2.9% | 32+27.5%3.1% | 31+50.8%3.5% | 30+114%3.7% | 30+214%3.7% | 25+563%3.3% | 21+578%3.2% | 14+462%2.5% | 9.5—1.7% | 3.8—1.8% | 3.1—1.3% | 2.5—1.0% | |
| Other intangible assets | 8.6—0.8% | 8.6—0.8% | 8.7—0.8% | 8.9—1.0% | 9.1—1.1% | — | 0—0.0% | — | — | — | — | — | — | |
| Total assets | 1,122—100% | 1,122+39.2%100% | 1,060+37.9%100% | 907+39.8%100% | 826+44.8%100% | 806+47.8%100% | 769+251%100% | 648+177%100% | 571+130%100% | 545—100% | 219—100% | 234—100% | 248—100% | |
| Accounts payable | 2.9—0.3% | 2.9+135%0.3% | 7.3+81.7%0.7% | 2.0−58.3%0.2% | 6.3+80.3%0.8% | 1.2−92.2%0.2% | 4.0+52.3%0.5% | 4.9−43.6%0.8% | 3.5−53.5%0.6% | 16—2.9% | 2.6r9.2—1.2% | 8.7—3.7% | 7.5—3.0% | |
| Current liabilities | 195—17.3% | 195+105%17.3% | 194+122%18.3% | 144+115%15.9% | 130+148%15.7% | 95+101%11.8% | 88+362%11.4% | 67+252%10.4% | 52+133%9.2% | 47—8.7% | 19—8.7% | 19—8.2% | 22—9.1% | |
| Total liabilities | 229—20.4% | 229+62.1%20.4% | 231+63.6%21.8% | 185+54.5%20.4% | 173+59.4%21.0% | 141+30.9%17.5% | 141+62.2%18.4% | 120+34.7%18.5% | 109+15.5%19.1% | 108—19.8% | 87—39.7% | 89—38.1% | 94—38.0% | |
| Retained earnings | −126—−11.3% | −126—−11.3% | −130—−12.3% | −194—−21.4% | −235—−28.5% | −198—−24.6% | −217—−28.2% | −281—−43.3% | −323—−56.6% | −336—−61.5% | −401—−183% | −384—−164% | −371—−150% | |
| Shareholders' equity | 893—79.6% | 893+34.4%79.6% | 829+32.1%78.2% | 721+36.5%79.6% | 653+41.3%79.0% | 664+52.0%82.5% | 628+375%81.6% | 528+265%81.5% | 462+201%80.9% | 437—80.2% | 132—60.3% | 145—61.9% | 154—62.0% | |
| Total liabilities and equity | 1,122—100% | 1,122+39.2%100% | 1,060+37.9%100% | 907+39.8%100% | 826+44.8%100% | 806+47.8%100% | 769+251%100% | 648+177%100% | 571+130%100% | 545—100% | 219—100% | 234—100% | 248—100% | |
| Shares outstanding | 77—— | 77+2.4%— | 76+2.4%— | 76+2.6%— | 75+2.9%— | 75+3.1%— | 74+7.0%— | 74+6.8%— | 73+6.4%— | 73—— | 69—— | 69—— | 69—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 4.9+79.3%0.6% | 1.4+54.8%0.7% | 1.2*+64.2%0.4% | 1.2*+99.5%0.6% | 1.1*+123%1.0% | 0.9+132%0.8% | 0.7*+289%0.6% | 0.6*+276%0.8% | 0.5*+323%0.9% | 0.4—13.8% | 0.2*—8.9% | 0.2—8.3% | 0.1*—0.1% | |
| Share-based compensation | 64+59.2%7.8% | 24+77.5%11.5% | 11*+11.5%3.7% | 12+18.7%5.8% | 17+151%15.2% | 13−43.6%11.1% | 9.6*+421%7.8% | 10+191%12.8% | 6.9+189%12.5% | 24—828% | 1.8—87.0% | 3.5—181% | 2.4*—3.0% | |
| Cash from operating activities | 123−18.4%15.1% | −4.9−109%−2.4% | 90*+60.5%31.0% | 46*−0.6%22.0% | −7.2*—−6.4% | 55—46.5% | 56*—45.4% | 46*—58.0% | −6.1*−104%−11.1% | −7.1—−248% | −12*—−584% | −25—−1319% | 135*—173% | |
| Capital expenditure | −8.8—−1.1% | −1.1—−0.5% | −2.3*—−0.8% | −2.0*—−1.0% | −3.5*—−3.1% | −6.2—−5.2% | −6.2*—−5.0% | −4.1*—−5.2% | −5.9*—−10.7% | −2.1—−73.3% | −1.1*—−50.5% | −0.6—−30.7% | −0.9*—−1.2% | |
| Intangible assets bought | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | |
| Cash from investing activities | −19—−2.3% | −1.1—−0.5% | −2.3*—−0.8% | −2.2*—−1.1% | −13*—−11.5% | −6.0—−5.0% | −6.2*—−5.0% | −5.0*−162%−6.3% | −8.0*−210%−14.6% | −1.1—−39.6% | −5.3*—−249% | 8.0—417% | 7.3*—9.3% | |
| Shares issued | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0*−100%0.0% | 201—7063% | 0*—0.0% | −0.8—−44.0% | 0.9*—1.1% | |
| Cash from financing activities | 91+82.7%11.2% | 36+589%17.3% | 33*+27.7%11.3% | 15*+11.5%7.2% | 7.8*+37.8%6.9% | 5.2−97.5%4.3% | 26*+1112%20.8% | 13*+2020%16.9% | 5.7*+499%10.4% | 203—7143% | 2.1*—99.9% | 0.6—32.8% | 0.9*—1.2% | |
| Change in cash | 196+11.3%24.0% | 30−45.8%14.4% | 121*+59.6%41.5% | 58*+7.3%28.1% | −12*—−10.9% | 55−72.0%45.8% | 76*—61.1% | 54*—68.6% | −8.4*−106%−15.3% | 195—6855% | −16*—−734% | −17—−869% | 143*—184% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2015. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Pharmacyclics#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreementBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersMaterial agreementShareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of May 26, 2015
FDA drug approvals: Pharmacyclics#
5 approved applications held, 1 of them new molecular entities; 0 approvals and 2 new uses in 2023.
| Approved | Drug | Kind |
|---|---|---|
| 2023-05-18 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-40) | New drug (NDA) |
| 2023-05-18 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-17) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-38) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-36) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-37) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-14) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-12) | New drug (NDA) |
| 2022-08-24 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-13) | New drug (NDA) |
| 2022-08-24 | ImbruvicaIbrutinib · NDA217003 | New drug (NDA) |
| 2020-12-18 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-32) | New drug (NDA) |
| 2020-12-18 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-9) | New drug (NDA) |
| 2020-04-21 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-30) | New drug (NDA) |
| 2020-04-21 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-6) | New drug (NDA) |
| 2019-01-25 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-26) | New drug (NDA) |
| 2019-01-25 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-2) | New drug (NDA) |
| 2018-08-24 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-24) | New drug (NDA) |
| 2018-08-24 | Imbruvicanew useIbrutinib · NDA210563 (SUPPL-1) | New drug (NDA) |
| 2018-02-16 | ImbruvicaIbrutinib · NDA210563 | New drug (NDA) |
| 2018-02-16 | ImbruvicaIbrutinib · NDA210563 | New drug (NDA) |
| 2017-12-20 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-20) | New drug (NDA) |
| 2017-08-02 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-17) | New drug (NDA) |
| 2017-01-18 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-16) | New drug (NDA) |
| 2016-05-06 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-10) | New drug (NDA) |
| 2016-05-06 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-13) | New drug (NDA) |
| 2016-03-04 | Imbruvicanew useIbrutinib · NDA205552 (SUPPL-7) | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (PHARMACYCLICS LLC), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 40% of workforce | Restructuring planSEC 8-K | “As a result of the corporate realignment, which is expected to be complete by March 31, 2008, the company will reduce its staff by approximately 40%.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Pharmacyclics compares in Biotechnology
- Revenue$730 M · higher than 90% of 647
- Net margin11.8% · higher than 79% of 408
- Revenue growth180.5% · higher than 88% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Pharmacyclics🇺🇸 | — | — | 11.8% | +180.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2014
- Balance sheet:
- As of December-2014
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, Wikimedia Commons, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Pharmacyclics? Verify and update this profile — free
Show Pharmacyclics's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.